<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01316458</url>
  </required_header>
  <id_info>
    <org_study_id>CSTI571BDE15</org_study_id>
    <nct_id>NCT01316458</nct_id>
  </id_info>
  <brief_title>Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy</brief_title>
  <official_title>An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      To investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with&#xD;
      rising PSA following radical prostatectomy, to produce a sustained biochemical response&#xD;
      during the first 6 months of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment.</measure>
    <time_frame>2 - 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>investigate the time to sustained biochemical response under the treatment of Glivec® in this patient population</measure>
    <time_frame>continuous</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>investigate duration of biochemical sustained response under the treatment with Glivec® in this patient population.</measure>
    <time_frame>continuous</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the response rates: number of patients with complete, partial and minor biochemical response and stable PSA</measure>
    <time_frame>continuous</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the time to clinical progression of this patient population treated with Glivec® at this dose and schedule.</measure>
    <time_frame>continuous</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To descriptively characterize the safety and tolerability of Glivec® administered at this dose and schedule to this patient population.</measure>
    <time_frame>continuous</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Prostatic Neoplasm</condition>
  <condition>Genital Neoplasms, Male</condition>
  <condition>Neoplasms, Abdominal</condition>
  <condition>Urogenital Neoplasms</condition>
  <condition>Genital Diseases, Male</condition>
  <condition>Prostatic Diseases</condition>
  <condition>Antineoplastic Agents</condition>
  <condition>Imatinib</condition>
  <arm_group>
    <arm_group_label>imatinib mesylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>STI571 (Glivec®)</intervention_name>
    <arm_group_label>imatinib mesylate</arm_group_label>
    <other_name>Glivec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  who are 18 years of age or older.&#xD;
&#xD;
          -  who have undergone radical prostatectomy within 2 years prior to PSA progression .&#xD;
&#xD;
          -  exhibiting two consecutive rises in PSA levels relative to a previous reference value,&#xD;
             separated by 14 days.&#xD;
&#xD;
        The first measurement must occur 14 days after the reference value und must be at least 20%&#xD;
        above the reference value. The reference value must be at least 0.4 ng/ml. The second&#xD;
        confirmatory measurement taken 14 days after the first measurement must be greater than the&#xD;
        first measurement.&#xD;
&#xD;
          -  with a Karnofsky Performance Score (KPS) greater than or equal to 90 (Appendix 5).&#xD;
&#xD;
          -  with the following hematologic lab values: ANC greater than or equal to 1500/mm3, Hgb&#xD;
             greater than or equal to 10g/dL, PLT greater than or equal to 100x109/L.&#xD;
&#xD;
          -  with the following biochemistry lab values: total bilirubin &lt; 1.5 ULN, SGOT, SGPT less&#xD;
             than or equal to 2.5 ULN, serum creatinine less than or equal to 1.5 ULN.&#xD;
&#xD;
          -  willing to employ an effective barrier method of contraception during the study&#xD;
             duration and for 3 months following discontinuation of study drug (for patients of&#xD;
             reproductive potential).&#xD;
&#xD;
          -  with a life expectancy of &gt; 6 months.&#xD;
&#xD;
          -  who have provided written informed consent pursuant to local regulatory requirements&#xD;
             prior to initiation of any study procedure.&#xD;
&#xD;
        with a Gleason Score &gt; 6 in the prostatectomy specimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  with a history of another malignancy within 5 years prior to study entry, except&#xD;
             curatively treated non-melanotic skin cancer, unless written approval is obtained by&#xD;
             the sponsor.&#xD;
&#xD;
          -  with prior hormonal therapy&#xD;
&#xD;
          -  who require therapy with warfarin or analgesics of the morphine class or higher (see&#xD;
             Section 3.4.4).&#xD;
&#xD;
          -  with a known diagnosis of HIV, hepatitis B, or hepatitis C infection.&#xD;
&#xD;
          -  who have had a major surgery within 2 weeks prior to study entry.&#xD;
&#xD;
          -  with severe, unstable, or uncontrolled medical disease which would confound diagnoses&#xD;
             or evaluations required by the protocol, including severe cardiac insufficiency (NYHA&#xD;
             III or IV, see Appendix 2), uncontrolled diabetes, chronic hepatic or renal disease,&#xD;
             and active uncontrolled infection.&#xD;
&#xD;
          -  with a history of noncompliance to medical regimens or inability or unwillingness to&#xD;
             return for all scheduled visits.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novarts Investigative Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Borken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fürth</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gardelegen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novarts Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wesel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://annonc.oxfordjournals.org/content/19/suppl_8/viii187.full.pdf+html</url>
    <description>Embase 70062155</description>
  </link>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>March 14, 2011</study_first_submitted>
  <study_first_submitted_qc>March 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2011</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer,</keyword>
  <keyword>radical prostatectomy,</keyword>
  <keyword>PSA rise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Urogenital Neoplasms</mesh_term>
    <mesh_term>Genital Neoplasms, Male</mesh_term>
    <mesh_term>Abdominal Neoplasms</mesh_term>
    <mesh_term>Prostatic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

